Endo Pharmaceuticals filed suit against Lupin on July 28, 2017 alleging infringement of patents related to Par’s Nascobal cyanocobalamin nasal spray. The suit was filed in the United States District Court for the Eastern District of Texas and was assigned to Judge Rodney Gilstrap.
The patents cited in the suit include US patents 7,229,636; 7,404,489; 7,879,349; 8,003,353; 8,940,714; and 9,415,007. Each of those patents is titled “Cyanocobalamin low viscosity aqueous formulations for intranasal delivery.”
The FDA approved the current unit dose version of Nascobal for the treatment of pernicious anemia and other vitamin B12 deficiencies in June 2014, and Endo subsidiary Par Pharmaceuticals launched the product in 2015.